Published in Immunity on May 17, 2016
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. J Hematol Oncol (2017) 0.99
PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. J Clin Invest (2017) 0.98
Advances in Cancer Immunotherapy in Solid Tumors. Cancers (Basel) (2016) 0.85
A distinct innate lymphoid cell population regulates tumor-associated T cells. Nat Med (2017) 0.79
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell (2016) 0.78
Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations. Blood (2017) 0.78
PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment. Front Immunol (2016) 0.78
LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci Immunol (2017) 0.78
ICOS Co-Stimulation: Friend or Foe? Front Immunol (2016) 0.77
Immune deficiency and autoimmunity in patients with CTLA-4 mutations. Clin Exp Immunol (2017) 0.76
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis. Ann Neurol (2016) 0.75
Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses. Front Immunol (2017) 0.75
The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications. Oncoimmunology (2017) 0.75
Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease. Front Immunol (2017) 0.75
Crystal Structures and Thermodynamic Analysis Reveal Distinct Mechanisms of CD28 Phosphopeptide Binding to the SH2 Domains of Three Adaptor Proteins. J Biol Chem (2016) 0.75
In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network. J Biol Chem (2017) 0.75
B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment. Oncoimmunology (2017) 0.75
Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. Immunotherapy (2017) 0.75
Developing Cures: Targeting Ontogenesis in Cancer. Trends Cancer (2017) 0.75
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open (2017) 0.75
Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model. JCI Insight (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 13.00
CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008) 12.67
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell (2006) 9.24
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med (2006) 8.18
A theory of self-nonself discrimination. Science (1970) 7.99
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature (2007) 7.04
CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol (2002) 6.94
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell (2013) 6.30
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol (2003) 5.47
Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med (1999) 5.26
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
A new member of the immunoglobulin superfamily--CTLA-4. Nature (1987) 5.10
CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 4.97
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (2011) 4.96
Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol (2011) 4.78
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 4.42
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41
Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet (2005) 4.23
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol (2001) 4.10
A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet (2002) 4.03
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med (1992) 3.77
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47
The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet (1996) 3.37
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A (2001) 3.32
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol (2003) 3.18
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell (2015) 3.03
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A (2003) 3.02
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 2.95
CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol (1991) 2.92
Characterization of mouse and human B7-H3 genes. J Immunol (2002) 2.86
Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol (1999) 2.77
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett (2004) 2.77
Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol (2011) 2.76
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 2.76
Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity (1996) 2.74
Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol (1996) 2.69
Characterization of CTLA-4 structure and expression on human T cells. J Immunol (1993) 2.68
AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science (2015) 2.62
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 2.58
Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol (2006) 2.50
Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity (2011) 2.49
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 2.49
Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol (1988) 2.45
The interaction properties of costimulatory molecules revisited. Immunity (2002) 2.43
FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat Med (2014) 2.35
Murine B7-H3 is a negative regulator of T cells. J Immunol (2004) 2.33
A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci (1975) 2.33
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal (2012) 2.24
Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol (2004) 2.23
Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol (2006) 2.15
An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity (2004) 2.00
Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics (1994) 1.96
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun (2014) 1.95
T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J (2006) 1.92
CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol (1992) 1.91
CTLA-4 in autoimmune diseases--a general susceptibility gene to autoimmunity? Genes Immun (2000) 1.91
Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol (2003) 1.82
NFATc1 regulates PD-1 expression upon T cell activation. J Immunol (2008) 1.81
CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab (1997) 1.78
B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol (2004) 1.78
Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci U S A (2008) 1.77
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med (2011) 1.77
MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol (2009) 1.76
Protein kinase C-η controls CTLA-4-mediated regulatory T cell function. Nat Immunol (2014) 1.76
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res (2009) 1.74
The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity (2000) 1.74
The B7 family of immune-regulatory ligands. Genome Biol (2005) 1.74
The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res (2005) 1.73
B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol (2009) 1.71
CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol (2009) 1.70
Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity (2004) 1.70
Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol (1996) 1.68
A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol (1999) 1.66
IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol (2011) 1.64
The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity (2014) 1.64
A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem (2002) 1.61
Fine mapping, gene content, comparative sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for Idd5.1 and Idd5.2 in the nonobese diabetic mouse. J Immunol (2004) 1.59
A native soluble form of CTLA-4. Cell Immunol (2000) 1.57
Mouse B7-H3 induces antitumor immunity. Gene Ther (2003) 1.57
Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity (2014) 1.54
PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J Clin Invest (2010) 1.53
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity (2016) 1.11
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med (2017) 1.08